The short answer
Mochi Health is our top pick for first-timers. Score 7.6 of 10. Flat $178 per month at every dose, month-to-month with self-serve online cancel, and a clinician review that catches the contraindications fast async intakes miss. If month one is rough, you walk without losing a non-refundable upfront fee.
The short version
First-time GLP-1 patients face a different problem than refill patients. You don't know yet whether you tolerate the molecule. You don't know your maintenance dose. You don't know if your insurance will cover a refill in month three. The right program for a first-timer absorbs that uncertainty: predictable cash-pay pricing at every dose tier, no annual lock-in, a clinician who screens for the contraindications a fast async intake skips. The wrong program optimizes for sign-up speed at the expense of the screening that catches the 5 to 10 percent of patients who shouldn't be on a GLP-1 in the first place.
What we considered
- Pricing transparency at every dose tier (no surprise repricing on titration)
- Clinical screening depth (catches contraindications a fast async intake skips)
- No lock-in (so month-one discontinuation doesn't cost you a 6-month commitment)
- Honest about compounded vs branded medication path
- Mobile-friendly intake (most first-time patients shop on their phone)
Top pick: Mochi Health
Mochi's flat $178 per month at every dose, online cancel and contraindication-screening intake make it the cleanest path for a patient who hasn't been on a GLP-1 before. The compounded medication path is the trade-off; if you specifically want brand Wegovy or Zepbound, the runner-up picks fit better.
Read the full Mochi Health review →
Why Mochi Health won this category
Mochi solves the three problems that matter most for a first-time GLP-1 patient. The price is flat across the entire titration ladder. You pay the same $178 at 0.25 mg as at 2.4 mg semaglutide. Most first-timers don't realize that other programs reprice as you titrate up, and the headline starter price they signed up on bears no resemblance to month three's bill. Mochi's flat structure removes that surprise.
The cancellation terms are clean. No minimum commitment. No prepay. Online self-serve cancel that actually cancels, not phone-only with retention upsells. About one in ten first-time GLP-1 patients discontinue inside the first 30 days due to gastrointestinal side effects, per the registration trials. A program that locks you into 6 or 12 months ahead of that risk window is betting against you. Mochi doesn't.
The clinical review is the part most cheap cash-pay programs skip. Mochi's intake includes contraindication screening (personal or family history of medullary thyroid cancer, MEN-2 syndrome, history of pancreatitis, severe gastroparesis) and a clinician sign-off before the script ships. The intake takes longer than Hims, but the screening that catches the patients who shouldn't be on a GLP-1 is the part that earns clinical depth in our scoring framework.
The compounded medication path is the trade-off. Mochi prescribes compounded semaglutide from 503A pharmacies, not branded Wegovy. The active molecule is the same, but the regulatory exposure is different. The FDA declared the semaglutide shortage resolved in October 2024, and 503A compounded semaglutide now operates under a narrower regulatory window than it did in 2023 to early 2024. Mochi has publicly disclosed their pharmacy partners and their continuity plan if compounded supply is disrupted, which is unusual for the category.
Who this pick isn't for
Mochi is not the right pick if you have insurance that already covers Wegovy or Zepbound. Mochi is cash-pay only. They don't bill insurance. If your employer plan or Medicare Advantage covers GLP-1 weight loss with prior authorization, you'll pay less out of pocket through PlushCare or Form Health than $178 a month at Mochi. Run your formulary check before signing up.
Mochi is also not the right pick if you specifically want brand Wegovy or Zepbound, not compounded. Some patients prefer the FDA-approved manufactured product for regulatory clarity, predictable supply or because they tried compounded and it didn't suit them. For brand-only first-timers, Ro Body's $299 per month LillyDirect Zepbound path or PlushCare's insurance-billed Wegovy are better fits.
And it's not the right pick if your medical history is complex enough that you need a primary-care relationship, not a single-condition telehealth specialist. Patients with multiple metabolic conditions (T2D plus hypertension plus dyslipidemia plus PCOS), cardiovascular history that needs coordination or an existing endocrinologist who needs labs shared, are better served by Knownwell or Form Health where the clinician handles more than just the GLP-1 prescription.
Runner-up: Form Health
Form Health is the strongest runner-up for first-timers with insurance: board-certified obesity medicine, the highest documented PA approval rate in the chart, and a clinical workup that surfaces comorbidities you didn't know counted.
Read the full Form Health review →
Top 3 compared
| Program | Score | Starts from | Lock-in | Time to Rx |
|---|---|---|---|---|
| Mochi Health | 7.6 | $178/mo | Month-to-month | 3 days |
| Form Health | 7.6 | $299/mo | Month-to-month | 7 days |
| PlushCare | 7.2 | $19.99/mo | Month-to-month | 1 day |
Other strong picks
Frequently asked
How do I know if I shouldn't take a GLP-1?
The labeled contraindications are a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a hypersensitivity to semaglutide or tirzepatide. Relative cautions include history of pancreatitis, severe gastroparesis, active gallbladder disease and pregnancy or planned pregnancy. A program with proper screening will ask about these; if your intake doesn't, that's a sign the program prioritized sign-up speed over safety.
What does the first month actually feel like?
Most patients start at the lowest dose (0.25 mg semaglutide weekly, or 2.5 mg tirzepatide weekly). Nausea is the most common first-month side effect, reported by roughly 40 to 45 percent of patients in the registration trials, usually peaking in the first 2 to 4 weeks and resolving as you stabilize. Appetite suppression typically kicks in within the first 7 to 14 days. Weight loss in month one averages 2 to 4 pounds; the bigger numbers come at higher doses in months 3 to 12.
Will I have to stay on it forever?
Most patients who stop a GLP-1 regain a substantial fraction of the weight they lost within 12 months, per the STEP-4 trial extension data. Plan financially for long-term treatment from the start. If your program locks you into 12 months but you can't afford year five, you bought the wrong thing.
Is compounded semaglutide the same as Wegovy?
The active molecule, semaglutide, is identical. The regulatory pathway is not. Wegovy is manufactured by Novo Nordisk under FDA new-drug approval. Compounded semaglutide is mixed by 503A pharmacies under prescription. The cash-pay savings are real (often $150 to $300 a month) but compounded operates in a narrower regulatory window after the FDA declared the semaglutide shortage resolved in October 2024. Our compounded explainer covers the trade-offs in depth.
What if month one doesn't go well?
Mochi is month-to-month with online self-serve cancel and no prepay. If you cancel inside month one, you don't pay for month two. Programs with 3-month, 6-month or 12-month commitments charge you for unused months. Always read the cancellation policy before sign-up; about 10 to 15 percent of GLP-1 patients discontinue inside the first 30 days, almost always due to side effects.
Should I just ask my regular doctor?
If your primary care doctor is comfortable prescribing GLP-1s and your insurance covers it, that's almost always a better starting point than a telehealth program. PCPs already have your medical history. Telehealth is the right choice when you don't have a PCP, your PCP refuses to prescribe weight-loss GLP-1s, or your insurance won't cover the medication and the cash-pay telehealth price beats the PCP-prescribed retail price. Our primary-care vs telehealth article covers when each path makes sense.
How long before I see weight loss?
Appetite suppression usually starts within the first 1 to 2 weeks. Visible scale movement starts around week 3 to 4. Clinically meaningful loss (5 percent of body weight) typically lands at week 12 to 16 at therapeutic doses. The STEP-1 trial showed mean 14.9 percent body-weight loss with semaglutide 2.4 mg at 68 weeks. SURMOUNT-1 showed mean 20.9 percent with tirzepatide 15 mg at 72 weeks. Real-world losses are lower because adherence varies.
Sources
- Wilding JP, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM 2021 (STEP-1 trial)
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. NEJM 2022 (SURMOUNT-1 trial)
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight maintenance. JAMA 2021 (STEP-4 extension)
- FDA: Wegovy prescribing information (semaglutide injection)
Related
